A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS.

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms ORACLE-MS
  • Sponsors EMD Serono
  • Most Recent Events

    • 09 Aug 2017 This study has been discontinued in belgium as per European Clinical Trials Database.
    • 27 Jun 2017 Results of an integrated analysis from three studies (ORACLE-MS, CLARITY, and CLARITY Extension) presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Longitudinal (48 weeks) evaluation of peripheral blood lymphocyte subtypes from patients of ORACLE-MS, CLARITY and CLARITY Extension; results presented at the 3rd Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top